{
    "Trade/Device Name(s)": [
        "B\u00dcHLMANN fCAL turbo",
        "BUHLMANN fCAL\u00ae turbo"
    ],
    "Submitter Information": "B\u00dcHLMANN Laboratories AG",
    "510(k) Number": "K190784",
    "Predicate Device Reference 510(k) Number(s)": [
        "K181012"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NXO"
    ],
    "Summary Letter Date": "June 25, 2019",
    "Summary Letter Received Date": "March 27, 2019",
    "Submission Date": "March 25, 2019",
    "Regulation Number(s)": [
        "21 CFR 866.5180"
    ],
    "Regulation Name(s)": [
        "Fecal calprotectin immunological test system"
    ],
    "Analyte Class(es)": [
        "immunology"
    ],
    "Analyte(s)": [
        "Calprotectin (MRP8/14)"
    ],
    "Specimen Type(s)": [
        "Human stool"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Clinical chemistry analyzers",
        "Roche cobas c501",
        "Roche cobas c502"
    ],
    "Method(s)/Technology(ies)": [
        "Particle-enhanced turbidimetric immunoassay (PETIA)",
        "Immunoparticle agglutination",
        "Automated clinical chemistry analyzer"
    ],
    "Methodologies": [
        "Immunoassay",
        "Turbidimetry"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator",
        "Control",
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for B\u00dcHLMANN fCAL turbo, a PETIA for quantifying fecal calprotectin in stool to aid in IBD diagnosis.",
    "Indications for Use Summary": "Quantitative measurement of fecal calprotectin in human stool to aid in diagnosis of inflammatory bowel disease (Crohn\u2019s disease and ulcerative colitis) and differentiation from irritable bowel syndrome in conjunction with other laboratory and clinical findings.",
    "fda_folder": "Immunology"
}